Literature DB >> 21807360

Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke.

Andria L Ford1, Jin-Moo Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21807360      PMCID： PMC3159841          DOI： 10.1016/j.brainres.2011.07.001

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


× No keyword cloud information.
  17 in total

Review 1.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

Authors: 
Journal:  Stroke       Date:  1999-12       Impact factor: 7.914

Review 2.  Recommendations for clinical trial evaluation of acute stroke therapies.

Authors: 
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

3.  MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.

Authors:  Shigeru Matsuura; Yasuhiro Egi; Satoshi Yuki; Takashi Horikawa; Hiroyuki Satoh; Toshiaki Akira
Journal:  Brain Res       Date:  2011-06-23       Impact factor: 3.252

4.  Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection.

Authors:  Louise D McCullough; Zhiyuan Zeng; Kathleen K Blizzard; Indira Debchoudhury; Patricia D Hurn
Journal:  J Cereb Blood Flow Metab       Date:  2005-04       Impact factor: 6.200

5.  Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.

Authors:  M Endres; Z Q Wang; S Namura; C Waeber; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

Review 6.  Clinical perspectives of PARP inhibitors.

Authors:  Grazia Graziani; Csaba Szabó
Journal:  Pharmacol Res       Date:  2005-07       Impact factor: 7.658

7.  Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.

Authors:  M J Eliasson; K Sampei; A S Mandir; P D Hurn; R J Traystman; J Bao; A Pieper; Z Q Wang; T M Dawson; S H Snyder; V L Dawson
Journal:  Nat Med       Date:  1997-10       Impact factor: 53.440

Review 8.  Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion.

Authors:  C Szabó; V L Dawson
Journal:  Trends Pharmacol Sci       Date:  1998-07       Impact factor: 14.819

9.  Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.

Authors:  Jonathan W B Marshall; Rosalyn M Cummings; Laura J Bowes; Rosalind M Ridley; A Richard Green
Journal:  Stroke       Date:  2003-08-14       Impact factor: 7.914

10.  Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects.

Authors:  C Szabó; L H Lim; S Cuzzocrea; S J Getting; B Zingarelli; R J Flower; A L Salzman; M Perretti
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307
View more
  9 in total

Review 1.  Sex differences in stroke therapies.

Authors:  Farida Sohrabji; Min Jung Park; Amanda H Mahnke
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 2.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

Authors:  Xin Luo; W Lee Kraus
Journal:  Genes Dev       Date:  2012-03-01       Impact factor: 11.361

Review 3.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

4.  PARP inhibitors.

Authors:  Maheen Anwar; Hafiz Muhammad Aslam; Shahzad Anwar
Journal:  Hered Cancer Clin Pract       Date:  2015-01-17       Impact factor: 2.857

Review 5.  Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases.

Authors:  Hun Taeg Chung; Yeonsoo Joe
Journal:  Integr Med Res       Date:  2014-10-02

6.  Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells.

Authors:  Paulina Gil-Kulik; Ewa Dudzińska; Elżbieta Radzikowska-Büchner; Joanna Wawer; Mariusz Jojczuk; Adam Nogalski; Genowefa Anna Wawer; Marcin Feldo; Wojciech Kocki; Maria Cioch; Anna Bogucka-Kocka; Mansur Rahnama; Janusz Kocki
Journal:  BMC Cancer       Date:  2020-05-18       Impact factor: 4.430

Review 7.  Effects of NAD+ in Caenorhabditis elegans Models of Neuronal Damage.

Authors:  Yuri Lee; Hyeseon Jeong; Kyung Hwan Park; Kyung Won Kim
Journal:  Biomolecules       Date:  2020-07-02

8.  Inhibiting poly(ADP-ribosylation) improves axon regeneration.

Authors:  Alexandra B Byrne; Rebecca D McWhirter; Yuichi Sekine; Stephen M Strittmatter; David M Miller; Marc Hammarlund
Journal:  Elife       Date:  2016-10-04       Impact factor: 8.140

9.  First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy Volunteers.

Authors:  Sungpil Han; Yo Han Kim; Hee Youn Choi; Dong-Jun Soh; Jeongmin Kim; Joonwoo Nam; Jong-Woo Kim; Kyun-Seop Bae; Hyeong-Seok Lim
Journal:  Drug Des Devel Ther       Date:  2020-08-05       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.